

Tropical Journal of Pharmaceutical Research May 2016; 15 (5): 973-979

ISSN: 1596-5996 (print); 1596-9827 (electronic)

© Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria.

All rights reserved.

Available online at <http://www.tjpr.org><http://dx.doi.org/10.4314/tjpr.v15i5.11>

Original Research Article

Leishmanicidal and cytotoxic activity of extracts and saponins from *Ilex laurina* (Aquifoliaceae)

Juan M Pérez¹, Sara Robledo^{2,3}, Wilson Cardona^{1*}, Fernando Alzate⁴, Diana Muñoz³ and Angie Herrera¹

¹Química de Plantas Colombianas, Instituto de Química, Facultad de Ciencias Exactas y Naturales, ²Programa de Estudio y Control de Enfermedades Tropicales (PECET), Sede de Investigación Universitaria, SIU, ³CIDEPRO-Center for Development of Products against Tropical Diseases, ⁴Grupo de Estudios Botánicos, Instituto de Biología, Facultad de Ciencias Exactas y Naturales, Universidad de Antioquia UdeA, Calle 70 No. 52-21, A.A 1226, Medellín, Colombia

*For correspondence: **Email:** wilson.cardona1@udea.edu.co; **Tel:** +574-2195653; **Fax:** +57-42330120

Received: 11 October 2015

Revised accepted: 12 April 2016

Abstract

Purpose: To evaluate the leishmanicidal and cytotoxic activity of alcohol and non-alcohol extracts and saponins from *Ilex laurina*.

Methods: Extracts were obtained by percolation with solvents of different polarities: hexane, dichloromethane, ethyl acetate and ethanol. The ethyl acetate extract was subjected to silica gel column chromatography eluting with a step gradient of dichloromethane-methanol. All products were evaluated *in vitro* for leishmanicidal activity against amastigotes of *leishmania panamensis* and cytotoxicity on U-937 cells.

Results: Two saponins were isolated from the ethyl acetate extract. The ethyl acetate extract showed high leishmanicidal activity against intracellular amastigotes of *L. panamensis* (EC_{50} , $7.5 \pm 1.5 \mu\text{g/mL}$) and low activity against axenic amastigotes (EC_{50} , $52.8 \pm 1.6 \mu\text{g/mL}$); this extract showed also high cytotoxicity (LC_{50} , $57.7 \pm 12.1 \mu\text{g/mL}$). Saponin 2 exhibited high activity against intracellular amastigotes (EC_{50} , $5.9 \pm 0.5 \mu\text{g/mL}$) but also showed high cytotoxicity on U-937 cells (EC_{50} , $25.7 \pm 6.1 \mu\text{g/mL}$). This compound showed similar leishmanicidal activity and cytotoxicity to meglumine antimoniate and amphotericin B, respectively, drugs currently used for the treatment of leishmaniasis.

Conclusions: Based on these results, *Ilex laurina* is a potential source of compounds that can lead to the development of new therapeutic alternatives against leishmaniasis.

Keywords: Leishmaniasis, Antiprotozoal, Saponin, *Ilex laurina*, Aquifoliaceae

Tropical Journal of Pharmaceutical Research is indexed by Science Citation Index (SciSearch), Scopus, International Pharmaceutical Abstract, Chemical Abstracts, Embase, Index Copernicus, EBSCO, African Index Medicus, JournalSeek, Journal Citation Reports/Science Edition, Directory of Open Access Journals (DOAJ), African Journal Online, Bioline International, Open-J-Gate and Pharmacy Abstracts

INTRODUCTION

Protozoan parasites are responsible for some of the most common and devastating diseases affecting humans and other mammals [1]. Among these diseases is leishmaniasis, which causes the most deaths after malaria [2], the reason why it has become a priority for the World Health Organization (WHO) [2].

Cutaneous leishmaniasis is endemic in the tropics and sub-tropics. It is often referred to as a group of diseases because of the broad spectrum of clinical manifestations, which range from small cutaneous nodules to gross mucosal tissue destruction. In America, cutaneous leishmaniasis can be caused by a multitude of *Leishmania* species, members of the *Vianna* subgenus, such as *L. (V.) panamensis*, *L. (V.) braziliensis*, and *L. (V.) guayanensis*, and members of the *Leishmania* subgenus, such as

L. (L.) amazonensis and *L. (L.) mexicana* [3]. Leishmaniasis caused by these *Leishmania* species are associated with recurrences or relapses and lesions are hard to heal in absence of treatment with specific drugs.

Classical antileishmanial drugs, pentavalent antimonials (meglumine antimoniate and sodium stibogluconate), pentamidine isothianate and miltefosine, show high toxicity, important side effects and are largely no longer effective because of the emergence of resistance in the parasites, thus becoming a major public health problem [4,5]. The lack of an effective leishmanicidal drug has evoked a renewed interest in medicinal plants as sources of new chemotherapeutic compounds that are more effective and have fewer side effects [6-9].

In order to find new drugs to combat this disease, we have studied extracts of *Ilex laurina*, a native Colombian plant that is distributed in the country in the north of Central and Western mountain ranges, from 1600 to 2900 m [10]. The *Ilex* genus belongs to the Aquifoliaceae family, comprising nearly 400 species of global distribution [11]. In Colombia, *Ilex* genus involves 35 species. *I. paraguariensis* or "yerba mate" is the most commercialized plant of South America because infusions of aerial parts show a variety of biological properties including antioxidant activity [12,13], cardiovascular effects [14,15], anti-parkinsonian effect [16], hypocholesterolemic, hepatoprotective [12], stimulant of the central nervous system and diuretic [17]. Different *Ilex* species are used as tea for protection against heart and liver diseases, brain dysfunction, and maintenance of proper body weight [18]. Tea of *Ilex guayusa* (named "guyasa") is used in southern Colombia (Amazon) and northern Ecuador as mild stimulant [19]. Antioxidant, antiproliferative and apoptotic activities of *Ilex laurina* infusion have also been reported [20].

Based on the broad spectrum of biological activities that have been reported for *Ilex* species and the need for new therapies against leishmaniasis, this study aimed at evaluating the leishmanicidal and cytotoxic activity of extracts and secondary metabolites from *I. laurina*.

EXPERIMENTAL

Plant materials

Leaves of *I. laurina* were collected during June 2013 in the village of Santa Elena, municipality of Medellín (Antioquia, Colombia) and identified by Dr. Fernando Alzate (Biology Institute, University

of Antioquia, Medellín, Colombia). A voucher specimen (no. Alzate-50622) was kept at University of Antioquia Herbarium.

Extraction and isolation

Powdered leaves (0.7 kg) of *I. laurina* were extracted successively with hexane, dichloromethane, ethyl acetate, and ethanol (10L each) in a percolator at room temperature and concentrated in vacuum to give the corresponding yields (66.6g [8.9 %], 124.3g [16.6 %], 107.3g [14.3 %] and 128.4g [17.1 %], respectively).

The ethyl acetate extract was subjected to silica gel column chromatography (5 × 80 cm) eluting with a step gradient of dichloromethane-methanol (100:0, 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80, 10:90, 0:100, each 500 mL), to obtain 10 fractions (F1 - F10) collected on the basis of their TLC profiles (dichloromethane-methanol-acetic acid 80:15:5). Fractions F4 and F8 were recognized as the most interesting ones, due to the appearance of black spots after spraying with universal reagent. Compound 1 (30 mg, 5.8 %) was isolated from F8 and compound 2 (35 mg, 3.9 %) from F4, by preparative TLC using dichloromethane-methanol-acetic acid (80:15:5) mixture.

Biological assays

The extracts and compounds were subjected to *in vitro* cytotoxicity on mammalian cells and leishmanicidal activity on axenic and intracellular amastigotes of *L. (V.) panamensis*.

In vitro cytotoxic activity in mammalian cells

The cytotoxicity of the products was assessed based on the viability of the human promonocytic cell line U937 (ATCC CRL-1593.2TM) evaluated by the MTT (3 - (4, 5-dimethylthiazol-2-yl) - 2, 5-diphenyltetrazolium bromide) method as described previously [21, 22]. Briefly, into each well of a 96-well cell-culture dishes were dispensed 100,000 cells/100 µL in RPMI-1640 supplemented with 10 % FBS and 100 uL of the corresponding concentrations of the extracts and saponins. Six double serial diluted concentrations were evaluated starting at 200 µg/mL. The cells were incubated at 37°C with 5 % CO₂ for 72 h in the presence of the extracts and saponins, and then the effect was determined by measuring the activity of the mitochondrial dehydrogenase by adding 10 µL/well of MTT solution (0.5 mg/mL) and incubating at 37 °C for 3 h. The reaction was stopped by adding a 50 % isopropanol solution with 10 % sodium dodecyl

sulfate for 30 min. Cell growth was determined based on the quantity of formazan produced, which was measured at 570 nm in a benchmark reader plate spectrophotometer (Bio-Rad Hercules, CA, USA). Cells cultured in the absence of products were used as cell growth controls, while cells cultured in presence of meglumine antimoniate and amphotericin B were used as cytotoxicity controls. Each concentration was tested in triplicate in two independent experiments.

Cytotoxicity was determined in terms of cell viability and cell growth inhibition obtained for each compound, amphotericin B or medium alone. Percentages of viability were calculated using Eq 1.

$$\text{Viability (\%)} = (A_t/A_c)100 \dots\dots\dots (1)$$

where A_t is the absorbance of treated cells and A_c (i.e., absorbance of control cells) corresponds to 100 % viability.

Cell growth inhibition was calculated as in Eq 2.

$$\text{Cell growth inhibition (\%)} = 100 - \text{viability (\%)} \dots\dots (2)$$

The results are expressed as 50 % lethal concentration (LC_{50}), i.e., the concentration of drug that gives half-maximal inhibition of cell growth. LC_{50} was calculated by Probit method [23]. The cytotoxicity of each product was graded according to the LC_{50} value, based on this own scale: High cytotoxicity (LC_{50} , < 50 $\mu\text{g/mL}$); moderate cytotoxicity (LC_{50} , > 50 to < 200 $\mu\text{g/mL}$), and potential no cytotoxicity (LC_{50} , >200 $\mu\text{g/mL}$).

***In vitro* leishmanicidal activity on axenic and intracellular amastigotes**

Axenic and intracellular amastigotes of *L. (V.) panamensis* strain transfected with the green fluorescent protein (MHOM/CO/87/UA140epirGFP) were used for the *in vitro* testing of leishmanicidal activity of each extract and saponins. Parasites in their promastigotes form were cultured in modified diphasic NNN medium and phosphate buffer saline (PBS) was used as liquid phase and incubated at 26 °C. In turn, axenic amastigotes were obtained from promastigotes cultured in Schneider's medium, pH 5.4 supplemented with 20 % FBS and incubated at 32 °C as described elsewhere [22]. Finally, intracellular amastigotes were obtained after infection of U937 cells with promastigotes; in brief, U937 cells were dispensed in 24-well plates at a concentration of 300,000 cells/well and were treated with 1 μM of

phorbol myristate acetate (PMA) for 48 h at 37 °C. Then, cells were infected with promastigotes of in stationary growth phase (day 5) at a ratio of 1:25 cell/parasite and incubated 3 h at 34 °C in 5 % CO_2 . Cells were washed twice with phosphate buffer solution (PBS) to eliminate not internalized parasites and fresh RPMI-1640 was added into each well (1 mL); plates were incubated again at 34 °C and 5 % CO_2 to allow intracellular differentiation to amastigotes form. After 24h of infection, cells were ready to be use in antileishmanial testing assay as described below.

Activity against axenic amastigotes

The ability of *L. laurina* to kill axenic amastigotes of *L. (V.) panamensis* was determined based on the viability of the parasites evaluated by the MTT method as described previously [21,22]. Axenic amastigotes obtained as described above were harvested, washed, and adjusted at 2×10^6 parasites/mL in fresh Schneider's medium with 20 % FBS. Into each well of a 96-well plate were dispensed 100 μL of parasite suspension (2×10^5 axenic amastigotes) and then 100 μL of each concentration of the extracts and saponins were added. Four serial dilution (base four) were prepared starting at 100 $\mu\text{g/mL}$ (100 - 25 - 6.25 - 1.56 $\mu\text{g/mL}$). Plates were incubated at 32 °C. After 72 h of incubation, the effect of products was determined by adding 10 μL /well of MTT and incubating at 32 °C for 3 h. The reaction was stopped as described above and the quantity of formazan produced was measured in a benchmark reader plate spectrophotometer (Bio-Rad Hercules, CA, USA) set at 570 nm. Parasites cultivated in the absence of the compounds and extracts but maintained under the same conditions were used as controls for growth and viability while parasites cultivated in the presence of meglumine antimoniate and amphotericin B were used as controls for leishmanicidal activity. Assays were performed at least twice with three replicates per each concentration tested. Antileishmanial activity was determined according reduction of parasite growth percentages obtained for each experimental condition. Parasite growth was calculated using Eq 3.

$$\text{Parasite growth (\%)} = (A_1/A_0)100 \dots\dots\dots (3)$$

where A_1 is the absorbance of treated axenic amastigotes) and A_0 . Is the absorbance of untreated axenic amastigotes, and corresponds to 100 % parasite growth. Thus parasite growth inhibition was calculated as in Equation 4.

$$\text{Parasite growth inhibition (\%)} = 100 - \text{parasite growth (\%)} (4)$$

The results are expressed as 50 % effective concentration (EC₅₀) which corresponds to the concentration of the drug that gives half-maximal reduction in parasite growth, calculated by Probit method [23]. The degree of leishmanicidal activity was established as convenience according to EC₅₀ values, using a self-designed scale: EC₅₀ < 20 µg/mL, moderate activity: EC₅₀ >20 to <50 µg/mL; and potential non activity: EC₅₀ > 50 µg/mL. Selectivity index (SI), also known as therapeutic index (TI) was calculated by the ratio of cytotoxicity to leishmanicidal activity, as in Eq 5.

$$SI = CL_{50}/CE_{50} \dots\dots\dots (5)$$

Activity against intracellular amastigotes

The effects of *I. laurina* extracts and saponins against intracellular amastigotes of *L. (V.) panamensis* were evaluated by flow cytometry using the methodology described by Pulido *et al* [24] and by Varela *et al* [25]. After 24 h of infection of U937 cells, culture medium was replaced by fresh RPMI medium containing each product at the corresponding concentration (four serial dilution base four, were prepared starting at a concentration not exceeding the LC₅₀ previously determined). Infected and treated cells were maintained at 34 °C and 5 % CO₂ for 72 h. After 72 h cells were removed from the bottom plate with a trypsin/EDTA (250 mg) solution and pulled of cells were centrifuged at 1100 rpm during 10 minutes at 4 °C; the supernatant was discarded and cells were washed with 1 mL of cold PBS, centrifuged at 1100 rpm for 10 minutes at 4 °C, the supernatant was discarded and cells were suspended in 500 µL of cold PBS. Cells were analyzed in an argon laser flow cytometer (Cytomics FC 500MPL Beckman Coulter, Brea, CA, USA) reading at 488 nm of excitation and 525 nm of emission and counting 20.000 events. Infected cells were determined according the positive events for green fluorescence (parasites). Infected cells treated with amphotericin B and meglumine antimoniate were used as control for antileishmanial activity (positive control) while infected cells incubated in culture RPMI 1640 medium alone were used as control for infection (negative control). Each concentration of all products were tested in triplicate in two independent experiments [22,24,25]. Antileishmanial activity was determined based on the reduction in infected cells obtained for each experimental condition. Parasitemia (i.e., infection) was calculated according Eq 6.

$$\text{Infection (\%)} = \frac{\text{infected and treated cells}}{\text{infected and untreated cells}} \times 100 \dots\dots\dots (6)$$

Percentage inhibition was calculated using Equation 7.

$$\text{Inhibition (\%)} = 100 - \% \text{ infection} \dots\dots\dots (7)$$

The results are also expressed as the EC₅₀, defined and calculated as stated above [23]. In this case, EC₅₀ corresponds to the concentration of drug that gives the half-maximal inhibition of intracellular parasites. The degree of leishmanicidal activity was also established according to EC₅₀ values, using the same self-designed scale described above. SI was also determined as stated above.

RESULTS

Identification of compounds isolated

The compounds were identified as saponins (Figure 1), by NMR and MS analysis. These compounds have already been reported [26-28].

Compound 1: ¹H NMR (300 MHz, pyridine-d₅): δ 1.09 (3H, d, J = 6.1 Hz), 1.27 (3H, s, CH₃), 1.29 (3H, s, CH₃), 1.43 (3H, s, CH₃), 1.73 (3H, s, CH₃), 1.77 (3H, s, CH₃), 2.97 (1H, s, H-18), 3.30 (1H, dd, J = 4, 11 Hz, H-3), 5.21 (1H, br s, 19-OH), 5.61 (1H, br t, H-12), 6.29 (1H, d, J = 6.8 Hz anomeric H). ¹³C NMR (75 MHz, pyridine-d₅): δ 38.4 (C₁), 28.5 (C₂), 77.2 (C₃), 48.6 (C₄), 56.4 (C₅), 23.7 (C₆), 32.4 (C₇), 40.1 (C₈), 46.8 (C₉), 37.1 (C₁₀), 24.0 (C₁₁), 128.9 (C₁₂), 138.2 (C₁₃), 42.0 (C₁₄), 28.3 (C₁₅), 26.1 (C₁₆), 47.2 (C₁₇), 53.7 (C₁₈), 72.6 (C₁₉), 41.6 (C₂₀), 26.2 (C₂₁), 37.0 (C₂₂), 180.1 (C₂₃), 23.7 (C₂₄), 11.6 (C₂₅), 18.4 (C₂₆), 25.5 (C₂₇), 177.7 (C₂₈), 26.5 (C₂₉), 15.8 (C₃₀), 94.7 (G-1), 74.8 (G-2), 77.6 (G-3), 70.1 (G-4), 78.0 (G-5), 61.6 (G-6). [M-H]⁻ m/z 663.4648.

Compound 2: ¹H NMR (300 MHz, pyridine-d₅): δ 1.07 (3H, d, J = 6.1 Hz), 1.08 (3H, s, CH₃), 1.09 (3H, s, CH₃), 1.27 (3H, s, CH₃), 1.41 (3H, s, CH₃), 1.69 (3H, s, CH₃), 2.98 (1H, s, H-18), 3.76 (2H, s, H₂₃), 4.30 (1H, dd, J = 5.5, 11 Hz, H-3), 5.61 (1H, s_{apparent}, H-12), 6.36 (1H, d, J = 7.5 Hz anomeric H). ¹³C NMR (75 MHz, pyridine-d₅): δ 38.2 (C₁), 26.0 (C₂), 73.1 (C₃), 41.9 (C₄), 48.2 (C₅), 17.9 (C₆), 32.3 (C₇), 39.8 (C₈), 47.9 (C₉), 36.5 (C₁₀), 23.3 (C₁₁), 128.1 (C₁₂), 138.2 (C₁₃), 41.5 (C₁₄), 28.3 (C₁₅), 25.1 (C₁₆), 48.1 (C₁₇), 53.6 (C₁₈), 72.4 (C₁₉), 41.3 (C₂₀), 25.7 (C₂₁), 36.9 (C₂₂), 66.3 (C₂₃), 11.3 (C₂₄), 16.3 (C₂₅), 15.2 (C₂₆), 23.4 (C₂₇), 177.2 (C₂₈), 25.8 (C₂₉), 14.9 (C₃₀), 94.3 (G-1), 72.2 (G-2), 77.1 (G-3), 69.8 (G-4), 77.2 (G-5), 61.1 (G-6). [M+Na]⁺ m/z 673.3937.




Figure 1: Chemical structure of ilexsaponin A, **1** and Rotungenoside, **2**

Table 1: *In vitro* leishmanicidal activity against axenic and intracellular amastigotes of *L. (V.) panamensis* and cytotoxicity of extract and saponins from *Ilex laurina*

Sample	LC ₅₀ (µg/ml) ^a		EC ₅₀ (µg/ml) ^b		SI ^c Axenic Amastigotes/ Intracellular Amastigotes
	U937 cells	Axenic Amastigotes	Intracellular Amastigotes		
Hexane	20.9 ± 4.3	> 100.0	> 100.0		<0.2
Dichloromethane	17.0 ± 3.5	20.3 ± 3.2	12.3 ± 0.8		0.8/1.4
Ethyl Acetate	57.7 ± 12.1	52.8 ± 1.6	7.5 ± 1.5		1.1/7.7
Ethanol	> 200.0	> 100.0	> 100.0		< 2.0
Ilexsaponin A, 1	> 200.0	> 100.0	> 100.0		< 2.0
Rotungenoside, 2	25.7 ± 6.1	41.6 ± 1.5	5.9 ± 0.5		0.6/4.3
Amphotericin B	26.6 ± 5.5	0.06 ± 0.01	0.04 ± 0.01		443.3/532
SbV ^d	495.9 ± 55.6	> 200.0	6.3 ± 0.9		< 2.0/78.7

Data represent the mean value +/- standard deviation. ^aLC₅₀: Lethal Concentration 50; ^bEC₅₀: Effective Concentration 50; ^cSI: selectivity index: LC₅₀ / EC₅₀; ^dSbV: pentavalent antimonial Meglumine antimoniate. Cytotoxic compound: LC₅₀ < 100 µg/mL. No cytotoxic compound: LC₅₀ > 200 µg/mL. Active compound: EC₅₀ < 20 µg/mL. Moderately Active: EC₅₀ > 20 - < 50 µg/mL; Non Active: EC₅₀ > 50 µg/mL.

Antileishmanial and cytotoxic activities

The leishmanicidal activity and cytotoxicity of extracts and saponins as well as meglumine antimoniate and amphotericin B, were evaluated following the method previously reported in the literature [21-25]. The leishmanicidal activity and cytotoxicity expressed as EC₅₀ and LC₅₀ values of extracts and saponins respectively, are shown in Table 1.

Based on the results shown in Table 1, the cytotoxicity of extracts varied among the solvent used. Thus, ethanolic extract was not cytotoxic for mammals U937 cells, exhibiting LC₅₀ > 200 µg/mL. The remaining extracts using ethyl acetate, hexane and dichloromethane were cytotoxic with LC₅₀ < 100 µg/mL. Amphotericin B was cytotoxic (LC₅₀ = 26.6 ± 5.5 µg/mL) and meglumine antimoniate was not cytotoxic (LC₅₀ = 495.9 ± 55.6 µg/mL).

Leishmanicidal activity was observed for ethyl acetate and dichloromethane extracts against intracellular amastigotes with EC₅₀ values < 20 µg/mL and moderately active against axenic amastigotes with values of EC₅₀ > 20 µg/mL. The hexane (although cytotoxic for U937 cells) and ethanolic extracts were not active against intracellular or axenic amastigotes of *L. (V.) panamensis* with EC₅₀ values > 100 µg/mL. Amphotericin B was highly active against both intracellular and axenic amastigotes of *L. (V.) panamensis* while meglumine antimoniate was also active against the intracellular form of the parasite.

DISCUSSION

The activity observed in axenic amastigotes and intracellular amastigotes of ethyl acetate extract (EC₅₀ < 60 µg/mL), suggests that this extract could be considered as promising in the search of new compounds against leishmaniasis. Based

on this result, we performed a fractionation of the ethyl acetate extract and separated a major secondary metabolites which were identified as ilex saponin A, **1** and rotungenoside, **2** (Figure 1) by NMR and MS analysis [26-28].

Saponin **2** showed similar leishmanicidal activity and cytotoxicity to meglumine antimoniate and amphotericin B, respectively, drugs currently used for the treatment of leishmaniasis. In addition, the compound exhibited a selectivity index ≥ 1 (SI = 4.3) leading to greater activity against the parasite than the toxicity against the host cell. Some studies have shown that these compounds are active against various types of leishmaniasis [29-32]. Saponin **1** was not active or cytotoxic against *L. (V.) panamensis* or U937 cells, respectively (Table 1). A possible explanation is the higher polarity due to carboxylic group, which could prevent the passage of the compound through the cell membrane.

The dichloromethane extract was the one that presented the best activity against axenic amastigotes of *L. (V.) panamensis*. Unfortunately, the cytotoxicity shown by this extract makes it a non-promising candidate in the search for new leishmanicidal compounds due to the risk of toxicity and no selectivity thereof. However, additional studies on cytotoxicity using other cell lines are needed in order discriminate whether the cytotoxicity showed by this extract is against tumoral or non-tumoral cells. The hexane extract showed activity against human cells but no activity against the *Leishmania* parasite and ethanolic extract was not potentially cytotoxic for the human U-937 cells but also was not active against *L. (V.) panamensis*; therefore, these extracts are not considered in the search for new compounds against cutaneous leishmaniasis.

CONCLUSION

Based on both leishmanicidal and cytotoxic activities, only ethyl acetate extract has potential to provide lead compounds for the development of new drugs to treat leishmaniasis. Two compounds have been isolated and identified in this study, both of which are saponins. Saponin **2** is a potential candidate for antileishmanial drug development based on its activity against *Leishmania* parasite. Although its cytotoxicity against U-937 cells is similar to amphotericin B, additional studies on cytotoxicity using other cell types are needed in order to determine whether the toxicity shown by this compound is against tumor or non-tumor cells. In addition, further studies are required to optimize the structure of

the promising molecule and to validate if the *in vitro* activity against *L. (V.) panamensis* demonstrated here would also be observed *in vivo*.

ACKNOWLEDGEMENT

This study was supported by the Universidad de Antioquia (Estrategia de Sostenibilidad, 2013-2014, grant CODI 808 and CIDEPRO).

CONFLICT OF INTEREST

No conflict of interest associated with this work.

CONTRIBUTION OF AUTHORS

We declare that this work was done by the authors named in this article and all liabilities pertaining to claims relating to the content of this article will be borne by the authors.

REFERENCES

1. Ouellette M. Biochemical and molecular mechanisms of drug resistance in parasites. *Trop Med Int Health* 2001; 6: 874-882.
2. <http://www.who.int/topics/leishmaniasis/en/>
3. Ameen M (2010) Cutaneous leishmaniasis: advances in disease pathogenesis, diagnostics and therapeutics. *Clin Exp Dermatol*, 35, 699-705.
4. Croft SL, Seifert K, Yardley V. Current scenario of drug development for leishmaniasis. *Ind J Med Res* 2006; 123: 399-410.
5. Croft SL, Sundar S, Fairlamb AH. Drug Resistance in Leishmaniasis. *Clin Microbiol Rev* 2006; 19: 111-126.
6. Arango V, Robledo S, Seon-Meniel B, Figadere B, Cardona W, Sáez J, Otálvaro F. Coumarins from *Galipea panamensis* and Their Activity against *Leishmania panamensis*. *J Nat Prod* 2010; 73: 1012-1014.
7. Alzate F, Jimenez N, Weniger B, Bastida J, Gimenez A, Ruiz G. Antiprotozoal Activity of Ethanol Extracts of Some *Bomarea* Species. *Pharm Biol* 2008; 46: 575-578.
8. Weninger B, Robledo S, Arango G, Deharo E, Aragón R, Muñoz V, Callapa J, Lobstein A, Anton R. Antiprotozoal activities of Colombian plants. *J Ethnopharmacol* 2001; 78:193-200.
9. Carmona D, Sáez J, Granados H, Pérez E, Blair S, Angulo A, Figadere B. Antiprotozoal 6- substituted -5, 6- dihydro α -pirones from *Raimondia CF. monoica*. *Nat Prod Res* 2003; 17: 275-280.
10. León JD, Vélez G, Yepes AP. Estructura y composición florística de tres robledales en la región norte de la cordillera central de Colombia. *Rev Biol Trop* 2009; 57: 1165-1182.

11. Heywood VH. *Flowering plants of the world. Mayflower Book. Elsevier Publisher, New York, 2007, NY; p 424.*
12. Filip R, Ferraro GE. Researching on new species of "Mate": *Ilex brevicuspis*: Phytochemical and pharmacology study. *Eur J Nut* 2003; 42: 50-54.
13. Gugliucci A. Antioxidant effects of *Ilex paraguariensis*: Induction of decreased oxidability of human LDL in vivo. *Biochem Biophys Res Commun* 1996; 224: 338-344.
14. Mosimann AL, Wilhelm-Filho D, Da Silva EL. Aqueous extract of *Ilex paraguariensis* attenuates the progression of atherosclerosis in cholesterol-fed rabbits. *Biofactors* 2006; 26: 59-70.
15. Schinella G, Fantinelli J C, Mosca S M. Cardioprotective effects of *Ilex paraguariensis* extract: Evidence for a nitric oxide-dependent mechanism. *Clin Nut* 2005; 24: 360-366.
16. Milioli EM, Cologni P, Santos CC, Marcos TD, Yunes VM, Fernandes MS. Effect of acute administration of hydroalcohol extract of *Ilex paraguariensis* St Hilaire (Aquifoliaceae) in animal models of Parkinson's disease. *Phytother Res* 2007; 21: 771-776.
17. Gonzalez A, Ferreira F, Vazquez A, Moyna P, Paz EA. Biological screening of Uruguayan medicinal plants. *J Ethnopharmacol* 1993; 39:217-720.
18. Heck CI, Mejia EG. Yerba mate tea (*Ilex paraguariensis*): A comprehensive review on chemistry, health implication, and technological consideration. *J Food Sci* 2007; 72: R138-R151.
19. Cardozo E, Ferrarese-Filho O, Cardozo L, Lucio M, Donaduzzi C, Sturion J. Methylxanthines and phenolic compounds in mate (*Ilex paraguariensis* St. Hil.) progenies grown in Brazil. *J Food Compos Anal* 2007; 20: 553-558.
20. Pérez JM, Maldonado ME, Rojano B, Alzate F, Sáez J, Cardona W. *Ilex laurina* and *Ilex paraguariensis*: Comparative Antioxidant, Antiproliferative and Apoptotic Effects on Colon Cancer Cells. *Trop J Pharm Res*, 2014;13:1279-1286.
21. Taylor VM, Muñoz DL, Cedeño DL, Vélez ID, Jones MA, Robledo SM. *Leishmania tarentolae*: utility as an in vitro model for screening of antileishmanial agents. *Exp Parasitol* 2010; 126: 471- 475
22. Taylor VM, Cedeño DL, Muñoz DL, Jones MA, Lash TD, Young AM, Constantino MH, Esposito N, Vélez ID, Robledo SM. In vitro and vivo studies of the utility of dimethyl and diethyl carbaporphyrin ketals in treatment of cutaneous leishmaniasis. *Antimicrob Agents Chemother* 2011; 55: 4755-4764.
23. Finney JD (1971) *Probit Analysis (3rd edition)* Cambridge University Press, Cambridge, UK
24. Pulido SA, Muñoz DL, Restrepo AM, Mesa CV, Alzate JF, Vélez ID, Robledo SM. Improvement of the green fluorescent protein reporter system in *Leishmania* spp. for the in vitro and in vivo screening of antileishmanial drugs. *Acta Trop* 2012; 122: 36-45.
25. Varela MRE, Muñoz DL, Robledo SM, Kolli BK, Dutta S, Chang KP, Muskus C. *Leishmania (Viannia) panamensis*: an in vitro assay using the expression of GFP for screening of antileishmanial drug. *Exp Parasitol*. 2009; 122: 134-139.
26. Radtke OA, Foo LY, Lu Y, Kiderlen A, Kolodziej H. Evaluation of Sage Phenolics for Their Antileishmanial Activity and Modulatory Effects on Interleukin-6, Interferon and Tumour Necrosis Factor- α -Release in RAW 264.7 Cells. *Z Naturforsch C* 2003; 58: 395-400.
27. Delmas F, Di Giorgio C, Elias R, Gasquet M, Azas Mshvildadze V, Dekanosidze G, Kemertelidze E, Timon-David P. Antileishmanial activity of three saponins isolated from ivy, α -hederin, β -hederin and hederacolchiside A1, as compared to their action on mammalian cells cultured in vitro. *Planta Medica* 2000; 66, 343-347.
28. Maes L, Vanden D, Germonprez N, Quirijnen L, Cos P, De Kimpe N, Van Puyvelde L. In vitro and In Vivo Activities of a Triterpenoid Saponin Extract (PX-6518) from the Plant *Maesa balansae* against Visceral *Leishmania* Species. *Antimicrob Agents Chemother* 2004; 48: 130-136.
29. Hidaka K., Ito M., Matsuda Y., Kohda H., Yamasaki K., Yamahara J., A Triterpene and Saponin From Roots of *Ilex Pubescens*. *Phytochemistry* 1987; 26: 2023-2027.
30. Zhao W., Wolfender J., Hostettmann K., Cheng K., Xu r., Qin G., Triterpenes and Triterpenoid Saponins From *Mussaenda Pubescens*. *Phytochemistry* 1997; 45: 1073-1078.
31. Nakatani M., Hatanaka S., Komura H., Kubota T., Hase T., The Structure of Rotungenoside, a New Bitter Triterpene Glucoside from *Ilex Rotunda*. *Bull Chem Soc Jpn* 1989; 62: 469-473.
32. Lagnika L, Weniger B, Vonthron-Senecheau C, Sanni A. antiprotozoal activities of compounds isolated from *croton lobatus* l. *Afr J Infect Dis* 2009; 3: 1-5.